Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Accutar Starts China Trial of Oral Chimeric Degrader for Prostate Cancer

publication date: Feb 23, 2023

Accutar Biotechnology enrolled the first patient in a China Phase I trial of AC0176, an oral chimeric degrader molecule aimed at Androgen Receptor (AR) protein in patients with metastatic Castration Resistant Prostate Cancer (mCRPC). The company uses its AI-based platform to discover drug candidates with greater high potency and selectivity. Accutar is already testing AC0176 in the US. In 2022, the New Jersey-Shanghai company started China trials for a breast cancer candidate, a chimeric degrader molecule designed to target ERα protein. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here